{
  "abstract": "Background: Targeted anti-tumor therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and immune checkpoint inhibitors, have improved clinical outcomes and survival across multiple cancers but are associated with clinically significant dermatologic, neurological, gastrointestinal, hematologic, and immune-related toxicities that compromise adherence and quality of life.\n\nObjectives: This scoping review aimed to systematically map the available evidence on nursing interventions used to prevent, monitor, and manage adverse effects associated with targeted anti-tumor therapies in adult cancer patients.\n\nMethods: Eligible studies were English-language publications conducted between 2015 and 2025 that focused on nurse-led or nursing-centered interventions addressing the adverse effects of targeted anti-tumor therapies in adult oncology populations. Data were charted using a standardized form and synthesized descriptively by intervention type and adverse-effect domain.\n\nResults: Of 742 records identified, 14 studies met the inclusion criteria. Study designs included two quasi-experimental studies and one randomized controlled trial protocol two cohort studies, seven narrative or integrative reviews, and two clinical practice guidelines. Five principal intervention categories were identified: patient education and self-management support; nurse-led oral targeted-drug management and continuity-of-care programs; home-based multidisciplinary interventions; telephone and telehealth-based toxicity monitoring; and symptom-specific supportive-care strategies. Across diverse settings, structured nursing interventions reduced toxicity burden, improved medication adherence, decreased unplanned healthcare use, and enhanced patient-reported quality of life and psychosocial outcomes.\n\nConclusion: Nurse-led interventions may have an important and promising role in supporting the safe and effective use of targeted anti-tumor therapies in adults with cancer. Integrating structured education, continuity of care, multidisciplinary collaboration, and telehealth-enabled monitoring into routine oncology practice may optimize toxicity management and support treatment adherence. Further multicenter trials are needed to evaluate nursing protocols for antibody-drug conjugate-induced neuropathy and immune-related adverse events and to examine long-term clinical and economic outcomes.\n\nSystematic Review Registration: https://osf.io/5nvfe/identifier , 5nvfe.",
  "abstract_shown": true,
  "affiliations": [
    "Faculty of Nursing, Al-Zaytoonah University",
    "Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University",
    "Department of Nursing, Faculty of Nursing, Salina Regional Health Center: Salina"
  ],
  "article_type": "systematic review",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Omar Alqaisi"
    },
    {
      "affs": [
        0
      ],
      "name": "Suhair Al-Ghabeesh"
    },
    {
      "affs": [
        1
      ],
      "name": "Mohammed Dibas"
    },
    {
      "affs": [
        0
      ],
      "name": "Yara Alwaqfi"
    },
    {
      "affs": [
        2
      ],
      "name": "Ghada Yaghmour"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0myb88zctser6.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1936674",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727521/?tool=EBI",
  "id": "0myb88zctser6",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1936674/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Systematic Review"
    ],
    [
      "openalex",
      "2730|Cancer survivorship and care"
    ]
  ],
  "openalex": "W7163043592",
  "pdf_url": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1936674/pdf",
  "pmcid": "PMC13727521",
  "pmid": "42978771",
  "published": "2026-10-20",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/0myb88zctser6.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:06Z",
      "native_id": "10.3389/fphar.2026.1936674",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1936674/full"
    },
    {
      "first_seen": "2026-11-04T15:20:46Z",
      "native_id": "PMC:PMC13727521",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13727521"
    },
    {
      "first_seen": "2026-11-06T12:23:23Z",
      "native_id": "PMC13727521",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fphar.2026.1936674"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer survivorship and care",
      "subfield": "oncology"
    }
  ],
  "title": "Nursing interventions for managing treatment-related adverse effects of targeted anti-tumor therapies in adult cancer patients: a scoping review",
  "title_text": "Nursing interventions for managing treatment-related adverse effects of targeted anti-tumor therapies in adult cancer patients: a scoping review",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T12:20:42Z",
  "url": "https://research.draconitic.com/paper/0myb88zctser6",
  "venue": "Frontiers in Pharmacology",
  "versions": []
}